ACCP - Store - IDSAP 2026

IDSAP 2026

Format to Purchase:

Member Price:
$88.00

Nonmember Price:
$132.00

ASHP members, please call (913)492-3311 to receive multi-book discounts at the member rate. Your ASHP membership number and expiration date are required.

Multi-book Discounts Available!

The latest release from the Infectious Diseases Self-Assessment Program (IDSAP) provides evidence-based updates and practical strategies for effectively managing infections and enhancing the application of antimicrobial stewardship principles and practices.

The target audience for IDSAP 2026 is board-certified infectious diseases pharmacists who provide care for individuals with or at risk for infectious diseases.

IDSAP 2026 comprises eight learning activities with a total available 16.5 continuing pharmacy education (CPE) credits. Each learning activity may be taken separately for BCIDP recertification credit. Book content was developed under the leadership of Faculty Panel Chair Krutika Mediwala Hornback, Pharm.D., BCIDP.

Continuing education activities in IDSAP cover the most recent published data (past 3–5 years) on a specific therapeutic area or patient-care problem. Learning content is provided as an electronic book (interactive PDF) with high-level updates in up to three formats, as appropriate to the topic:

Traditional chapters review the latest published evidence on a therapeutic or practice-related topic
Case series deliver learning content in sections, with each section bookended by a sample case and its explained answer
Recorded webcasts provide learning content as a PowerPoint presentation, accessed as an MP4 file as well as a PDF of slides and transcribed narrative

Every IDSAP release comes in two full-color online formats: (1) interactive PDFs you can save to your desktop or print; and (2) an e-media version you can view on an e-reader, tablet, iOS or Android smart phone.

All IDSAP activities are fully referenced, with clickable hyperlinks to literature compilers such as PubMed. Other links provide ready access to clinical practice guidelines, official recommendations, and patient assessment tools. Graphic features focus on pivotal studies, patient care scenarios, and take-home points that can be readily integrated into clinical practice.

Publisher: ACCP, 164 pages, May 2026; ISBN-13: 978-1-964074-38-2

Release Date: May 15, 2026
BCIDP Deadline: May 14, 2027

ACPE Deadline: May 15, 2029

Editor(s): Dodds Ashley ES, Gross AE
ISBN: 978-1-964074-38-2
Publication Year: 2026
Format: PDF and ePub

MORE PRODUCTS IN THIS SERIES

Chapter: Staphylococcus aureus

Expand clinical expertise with this comprehensive learning activity focused on Staphylococcus aureus management. It offers the opportunity to strengthen antimicrobial stewardship, optimize antibiotic selection and dosing, interpret rapid diagnostics, and apply evidence-based strategies for MRSA/MSSA bacteremia. Emphasizing OPAT, oral step-down therapy, and resistance mitigation, this program equips pharmacists to improve patient outcomes, reduce mortality, and enhance clinical decision-making in infectious diseases pharmacotherapy.

Chapter: Enterococcus

This comprehensive learning activity focuses on Enterococcus infections, emphasizing antimicrobial stewardship, resistance mechanisms, and evidence-based treatment strategies. The clinical pharmacist can strengthen skills in optimizing antimicrobial therapy, managing VRE, and improving patient outcomes in bloodstream infections and complex care settings. Designed to enhance clinical decision-making, pharmacotherapy optimization, and real-world application for improved infectious disease management and healthcare quality.

Chapter: Vancomycin Dosing

This advanced learning activity on vancomycin dosing and therapeutic drug monitoring focuses on AUC-guided dosing, pharmacokinetics/pharmacodynamics (PK/PD), and antimicrobial stewardship best practices. Participants build expertise in individualized dosing, nephrotoxicity risk mitigation, and managing special populations, improving clinical decision-making and patient outcomes in MRSA and serious infections through precision pharmacotherapy and evidence-based protocols.

Recorded Webcast: Surgical Prophylaxis

This advanced learning activity is designed to equip the clinical pharmacist with practical expertise in antimicrobial surgical prophylaxis, antibiotic stewardship, and pharmacokinetic dosing strategies to reduce surgical site infections (SSIs). Learners gain evidence-based skills in perioperative antibiotic selection, timing, redosing, and duration optimization, along with allergy management and outcomes improvement. Designed to enhance clinical decision-making, this program supports precision pharmacotherapy, patient safety, and improved healthcare outcomes.

Chapter: C. difficile Infection

This comprehensive learning activity on Clostridioides difficile infection (CDI) management features guideline-driven treatment, antimicrobial stewardship, and recurrence prevention strategies. Learners develop skills in pharmacotherapy selection (fidaxomicin, vancomycin), therapeutic drug decision-making, and microbiome-based interventions, including fecal microbiota products. Designed to enhance clinical outcomes, this program supports evidence-based practice, infection management, and optimized patient care in high-risk populations.

Chapter: Diagnostic Stewardship

This dynamic learning activity on diagnostic stewardship and antimicrobial stewardship integration focuses on optimizing diagnostic testing, clinical decision support, and evidence-based interventions. It can assist the clinical pharmacist in reducing overdiagnosis, inappropriate antibiotic use, and healthcare-associated infections. The learning activity is designed to build skills in implementation science, quality improvement, and EMR-driven strategies to enhance diagnostic accuracy, improve patient outcomes, and strengthen stewardship program performance.

Case Series: Collaborations with Clinical Microbiology

This learning activity focuses on antimicrobial stewardship, clinical microbiology collaboration, and rapid diagnostics. It highlights actionable strategies such as antibiogram optimization, susceptibility reporting, and clinical decision support to improve antibiotic selection and resistance management. Designed to build clinical pharmacy skills, this program strengthens diagnostic interpretation, evidence-based prescribing, and interprofessional care—driving improved patient outcomes and stewardship program success.

Chapter: Antimicrobial Stewardship Opportunities at Transitions of Care

This targeted learning activity on antimicrobial stewardship and transitions of care delivers practical strategies for medication optimization, discharge antibiotic management, and clinical decision support to reduce readmissions and improve patient outcomes. Featuring evidence-based prescribing, microbiology follow-up, and pharmacist-led interventions, this program strengthens clinical pharmacy skills, antimicrobial management, and quality improvement across inpatient and outpatient settings.

Faculty

Caroline Jozefczyk, Pharm.D., BCIDP
Infectious Diseases Clinical Pharmacist Specialist
Department of Pharmacy
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina

Reviewers

David B. Cluck, Pharm.D., FIDSA, FCCP, BCPS, BCIDP, AAHIVP
Professor of Pharmacy Practice
Department of Pharmacy Practice
East Tennessee State University – Bill Gatton College of Pharmacy
Johnson City, Tennessee

Entisar Almodyan, Pharm.D., BCPS, BCIDP, CMTMP, AAHIVP
Infectious Disease Clinical Pharmacist
Antimicrobial Stewardship Program Coordinator
Pharmacy Training Coordinator
Pharmaceutical Care Department
Maternity and Children Hospital, Hail Health Cluster
Saudi Arabia

Riley Williams, II, Pharm.D., BCIDP
Clinical Pharmacist Practitioner for Infectious Diseases
Department of Pharmacy
Oklahoma City VAHCS
Oklahoma City, Oklahoma

Faculty

Darrell Childress, Pharm.D., BCPS, BCIDP
Advanced Clinical Pharmacist
Infectious Diseases/Antimicrobial Stewardship
St. George Regional Hospital, Intermountain Health
St. George, Utah

Reviewers

Rachel A. Foster, Pharm.D., MBA, BCIDP
Advanced Clinical Pharmacist – Infectious Diseases
Department of Pharmacy
Intermountain Medical Center
Murray, Utah

Tho H. Pham, Pharm.D., BCIDP
Clinical Assistant Professor
Department of Pharmacy Practice
University of Arizona R Ken Coit College of Pharmacy
Antimicrobial Resistance/Antimicrobial Stewardship Lead
Office of Healthcare-associated Infections
Arizona Department of Health Services
Phoenix, Arizona

Faculty

Rachel S. Britt, Pharm.D., BCIDP
Clinical Pharmacy Specialist – Infectious Diseases
PGY2 Infectious Diseases Pharmacy Residency Program Coordinator
Department of Pharmacotherapy and Pharmacy Services
University Health System
San Antonio, Texas

Reviewers

W. Justin Moore, Pharm.D., MS, BCPS, BCIDP
Practice Coordinator, Antimicrobial & Diagnostic Stewardship
Clinical Pharmacist, Infectious Diseases
Northwestern Medicine Antimicrobial and Diagnostic
Stewardship Program
Chicago, Illinois

Bronagh P. Keane, MPharm, BCPS, BCIDP
Hospital Clinical Pharmacist
Department of Pharmacy
HSHS St Johns Hospital
Springfield, Illinois

Yehia Mahmoud El Khawly, Pharm.D., BCIDP
Clinical Pharmacist
Department of Pharmacy
Hamad Medical Corporation – Al Wakra Hospital
Doha, Qatar

Faculty

	Erin Weslander, Pharm.D., BCIDP Infectious Diseases Pharmacist Department of Pharmacy Northwestern Medicine Antimicrobial & Diagnostic Stewardship Program System Coordinator Northwestern Memorial Hospital Chicago, Illinois
	Jaime L. Borkowski, Pharm.D., BCIDP, BCPS Clinical Coordinator Antimicrobial and Diagnostic Stewardship Program Northwestern Memorial Healthcare Clinical Pharmacy Specialist, Antimicrobial Stewardship Antimicrobial and Diagnostic Stewardship Program Northwestern Medicine Delnor Hospital Chicago, Illinois

Reviewers

Clara Ni, Pharm.D., BCIDP
Clinical Pharmacy Specialist, ID/ASP
Division of Pharmacy Services
Children’s National Hospital
Washington, DC

Min Zhang, Pharm.D., BCPS, BCIDP
Pharmacy Clinical Specialist
Beth Israel Lahey Health
Clinical Medicine Pharmacist (Per Diem)
Boston Medical Center
Boston, Massachusetts

Jessica Cottreau, Pharm.D., BCPS, BCIDP
Associate Professor
Chair of Pharmacy Practice
Rosalind Franklin University College of Pharmacy
North Chicago, Illinois

Faculty

Emily Drwiega, Pharm.D., BCIDP, BCPS, AAHIVP
Clinical Assistant Professor of Pharmacy Practice
Department of Pharmacy Practice
University of Illinois at Chicago Retzky College of Pharmacy
Clinical Pharmacy Specialist
University of Illinois Hospital and Health System
Chicago, Illinois

Reviewers

Kelly Reveles, Pharm.D., Ph.D., BCIDP
Associate Professor
College of Pharmacy
The University of Texas at Austin
Austin, Texas
Adjoint Associate Professor
School of Medicine
University of Texas Health San Antonio
San Antonio, Texas

Kelli A. Kronsberg, Pharm.D., BCPS, BCIDP
Clinical Assistant Professor
Department of Pharmacy Practice and Science
University of Arizona R. Ken Coit College of Pharmacy
Phoenix, Arizona

James A. McCracken-Goncalves, Pharm.D., BCIDP, AAHIVP
Clinical Pharmacist
Department of Pharmacy
Children’s Hospital Colorado
Aurora, Colorado

Faculty

Kimberly C. Claeys, Pharm.D., Ph.D.
Associate Professor
Pharmacy Science and Health Outcomes Research
University of Maryland
Baltimore, Maryland

Reviewers

David R. Ha, Pharm.D., BCPS, BCIDP
Manager, Antimicrobial Stewardship
Quality and Infectious Diseases
Stanford Health Care and Stanford Medicine
Stanford, California

Lisa A. Krautstrunk, Pharm.D., BCPS, BCIDP
Clinical Specialist, Infectious Diseases
PGY2 Pharmacy Residency Program Director, Infectious Diseases
PGY1 Pharmacy Residency Program Coordinator
Dignity Health St. Rose Dominican Hospital – Siena Campus
Adjunct Faculty
Roseman University College of Pharmacy
Henderson, Nevada

Faculty

Hana Rac Winders, Pharm.D., BCIDP
Clinical Pharmacy Specialist
Department of Pharmacy
Prisma Health
Columbia, South Carolina

Reviewers

Cory M. Hale, Pharm.D., BCIDP
Clinical Pharmacist Specialist, Infectious Diseases
Clinical Pharmacy Service Line
UPMC
Pittsburgh, Pennsylvania

Kimberly Ann Pough, Pharm.D., MPH, BCPS, BCIDP
Antimicrobial Stewardship Pharmacist
Center for Healthcare Quality and Analytics
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Faculty

Sarah T. Withers, Pharm.D., MS, BCIDP
Clinical Pharmacy Specialist – Outpatient Parenteral Antimicrobial Therapy
Department of Pharmacy
Prisma Health
Greenville, South Carolina

Reviewers

Corey J. Medler, Pharm.D., MPH, BCIDP
Clinical Pharmacist, Infectious Diseases
Department of Pharmacy Services
UVA Health University Medical Center
Charlottesville, Virginia

Jessica L. Sobnosky, Pharm.D., BCPS, BCIDP
Clinical Pharmacist – Infectious Diseases and Antimicrobial Stewardship
PGY2 Infectious Diseases Residency Program Director
Department of Pharmacy
UK King’s Daughters
Ashland, Kentucky

Sara DiTursi, Pharm..D., BCPS, BCIDP
Clinical Pharmacy Specialist – Infectious Diseases
Catholic Health System – Kenmore Mercy Hospital
Buffalo, New York

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of BCIDP.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Target Audience: The target audience for IDSAP 2026 is pharmacotherapy specialists and advanced-level clinical pharmacists whose responsibilities may include providing care for individuals with or at risk for infectious diseases.

Chapter: Staphylococcus aureus Activity Number: 0217-9999-26-088-H01-P Contact Hour(s): 2.50 Activity Type: Application BasedLearning Objectives Evaluate Staphylococcus aureus infection and distinguish the mechanisms by which it causes disease. Develop optimal antimicrobial regimens for patients with various S aureus infections. Design an antimicrobial regimen for patients with deep-seated or persistent S aureus infections. Evaluate novel therapies for S aureus infections and their potential roles in treatment and prevention. Devise antimicrobial stewardship initiatives to improve treatment and outcomes related to S aureus infections.
Chapter: Enterococcus Activity Number: 0217-9999-26-089-H01-P Contact Hour(s): 2.50 Activity Type: Application BasedLearning Objectives Analyze the epidemiology of various Enterococcus infections. Evaluate Enterococcus resistance mechanisms and current microbiology breakpoint data. Develop optimal antimicrobial regimens for the treatment of various Enterococcus infections. Design antimicrobial stewardship strategies to optimize patient care for Enterococcus infections.
Chapter: Vancomycin Dosing Activity Number: 0217-9999-26-090-H01-P Contact Hour(s): 2.00 Activity Type: Application BasedLearning Objectives Evaluate pharmacokinetic (PK) characteristics and pharmacodynamic targets of vancomycin. Construct a vancomycin dosing regimen on the basis of patient-specific characteristics. Analyze the applications, advantages, and disadvantages of trough-based and AUC-based monitoring of vancomycin. Distinguish the PK alterations in special populations that affect vancomycin dosing regimens.
Recorded Webcast: Surgical Prophylaxis Activity Number: 0217-9999-26-091-H01-P Contact Hour(s): 1.50 Activity Type: Application BasedLearning Objectives Assess the data and opportunities for antibiotic stewardship in antimicrobial surgical prophylaxis. Evaluate pharmacokinetic goals and methods for dosing surgical prophylaxis. Differentiate the uses and efficacy of nonsystemic surgical prophylaxis.
Chapter: C. difficile Infection Activity Number: 0217-9999-26-092-H01-P Contact Hour(s): 2.00 Activity Type: Application BasedLearning Objectives Apply an understanding of Clostridioides difficile infection (CDI) pathophysiology, including how and why patients experience recurrence. Construct a medication plan for a patient with an initial episode of CDI. Distinguish the advantages and disadvantages of available medications/treatments for patients with recurrent CDI. Evaluate the latest strategies for the secondary prevention of CDI.
Chapter: Diagnostic Stewardship Activity Number: 0217-9999-26-093-H01-P Contact Hour(s): 2.50 Activity Type: Application BasedLearning Objectives Apply diagnostic stewardship principles to optimize diagnostic testing and antibiotic use in clinical practice. Evaluate available evidence on implementing diagnostic stewardship interventions. Evaluate and respond to challenges in prioritizing, implementing, and evaluating diagnostic stewardship interventions.
Case Series: Collaborations with Clinical Microbiology Activity Number: 0217-9999-26-094-H04-P Contact Hour(s): 2.00 Activity Type: Application BasedLearning Objectives Analyze the benefits, limitations, and clinical applications of different antibiogram types to support antimicrobial stewardship and patient care decisions. Design susceptibility testing or reporting interventions on the basis of patient or hospital challenges and opportunities. Describe the steps for implementing rapid diagnostic tests and explain the general benefits of their use, including the role of collaboration between microbiology and stewardship teams. Develop a collaborative plan to educate health care staff on infectious syndrome management, specimen collection best practices, test characteristics, and result interpretation.
Chapter: Antimicrobial Stewardship Opportunities at Transitions of Care Activity Number: 0217-9999-26-095-H01-P Contact Hour(s): 1.50 Activity Type: Application BasedLearning Objectives Identify different patient transitions through health care settings where opportunities for antimicrobial stewardship (AS) exist. Evaluate the effect of AS interventions at transitions of care (TOC) on the antimicrobial use process. Develop strategies for implementing AS interventions at TOC.

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.

Disclosures

Sample_Chapter.pdf

IDSAP 2026